Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 14;9(3):1671-1678.
doi: 10.1039/c8ra09755k. eCollection 2019 Jan 9.

Preparation of novel 1,2,3-triazole furocoumarin derivatives via click chemistry and their anti-vitiligo activity

Affiliations

Preparation of novel 1,2,3-triazole furocoumarin derivatives via click chemistry and their anti-vitiligo activity

Chao Niu et al. RSC Adv. .

Abstract

The extracts of Psoralea corylifolia L. were often used for the repigmentation of leukoderma (vitiligo) in traditional Uygur medicine thousands years ago. Nowadays, its active ingredient, furocoumarins, has been clinically applied since it exhibited strong photosensitivity. Thus, a new series of furocoumarin derivatives (8a-8o) containing 1,2,3-triazole were designed and synthesized based on our previous work. After biological evaluation for melanin contents and tyrosinase activity in B16 murine cells, the SAR was summarized. The results indicated that five compounds (8a, 8j, 8m-8o) were more potent than the positive control (8-MOP) on melanogenesis. Among them, 8a and 8o showed the best stimulating effect on tyrosinase activity as well, and were submitted for further pharmacological study of anti-vitiligo.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Fig. 1
Fig. 1. Vitiligo with typical lesions of the face and trunk.
Fig. 2
Fig. 2. Structures of commonly used drugs for vitiligo.
Fig. 3
Fig. 3. The plant of the Psoralea corylifolia L.
Fig. 4
Fig. 4. The structures of the furocoumarins used for vitiligo.
Fig. 5
Fig. 5. The SAR of furocoumarins on vitiligo.
Scheme 1
Scheme 1. Synthesis of furocoumarin derivatives containing 1,2,3-triazole (8a–8o). Reagents and conditions: (i) DMF, K2CO3, 70 °C (ii) ethyl acetoacetate, H2SO4, 60 °C (iii) 2-bromoacetophenone, K2CO3, acetone, reflux (iv) 4% KOH ethanolic solution, reflux (v) SeO2, xylene, reflux (vi): NaBH4, methanol, rt (vii): PBr3, THF, 0 °C-rt (viii): NaN3, CH3CN, reflux (ix) a–o, CuSO4·5H2O, Cu, t-BuOH : H2O = 1 : 3, 80 °C.
Fig. 6
Fig. 6. Stimulation of melanin content of B16 cells by 8a–8o. N means negative control; P means positive control (8-MOP); the B16 cells was treated with 50 μM different furocoumarin derivatives for 48 h. After that, melanin content was measured directly. Values are expressed as the mean ± SD of three separate experiments, P < 0.05.
Fig. 7
Fig. 7. Stimulation of tyrosinase activity of B16 cells by 8a–8o. N means negative control; P means positive control (8-MOP). B16 cells was treated with 50 μM different furocoumarin derivatives for 48 h. After that, tyrosinase activity was measured directly. The data are the mean ± SD of three experiments, P < 0.05.
Fig. 8
Fig. 8. The concentration dependent manner of 8a, 8o on melanin synthesis and tyrosinase activity. “◆”, “■” and “×”, “▲” means the effect of 8a, 8o on melanin synthesis (in blue) and tyrosinase activity (in red) separately at different concentration in B16 cells.

Similar articles

Cited by

References

    1. Ezzedine K. Eleftheriadou V. Whitton M. van Geel N. Lancet. 2015;386:74–84. doi: 10.1016/S0140-6736(14)60763-7. - DOI - PubMed
    1. Rodrigues M. Ezzedine K. Hamzavi I. Pandya A. G. Harris J. E. J. Am. Acad. Dermatol. 2017;77:1–13. doi: 10.1016/j.jaad.2016.10.048. - DOI - PubMed
    1. Ezzedine K. Lim H. W. Suzuki T. Katayama I. Hamzavi I. Lan C. C. E. Goh B. K. Anbar T. Silva de Castro C. Lee A. Y. Parsad D. van Geel N. Le Poole I. C. Oiso N. Benzekri L. Spritz R. Gauthier Y. Hann S. K. Picardo M. Taieb A. Pigm. Cell Melanoma Res. 2012;25:E1–E13. doi: 10.1111/j.1755-148X.2012.00997.x. - DOI - PMC - PubMed
    1. Laddha N. C. Dwivedi M. Mansuri M. S. Gani A. R. Ansarullah M. Ramachandran A. V. Dalai S. Begum R. Exp. Dermatol. 2013;22:245–250. doi: 10.1111/exd.12103. - DOI - PubMed
    1. Wang S. Jin R. Wang R. Hu Y. Dong X. Xu A. RSC Adv. 2016;6:106308–106315. doi: 10.1039/C6RA23172A. - DOI